摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

cis-bis(triflato)(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo-[5.5.2]tetradecane)cobalt(III) triflate | 1443429-83-1

中文名称
——
中文别名
——
英文名称
cis-bis(triflato)(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo-[5.5.2]tetradecane)cobalt(III) triflate
英文别名
——
cis-bis(triflato)(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo-[5.5.2]tetradecane)cobalt(III) triflate化学式
CAS
1443429-83-1
化学式
CF3O3S*C14H26CoF6N4O6S2
mdl
——
分子量
732.57
InChiKey
QDWORDCUGPMYGD-UHFFFAOYSA-K
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为反应物:
    描述:
    cis-bis(triflato)(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo-[5.5.2]tetradecane)cobalt(III) triflate 、 1-(chloromethyl)-5-hydroxy-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-2,3-dihydro-1H-pyrrolo[3,2-f]quinoline 在 吡啶 作用下, 以 甲醇 为溶剂, 反应 216.0h, 以84%的产率得到1-(chloromethyl)-3-(5,6,7-trimethoxyindol-2-ylcarbonyl)-2,3-dihydro-1H-pyrrolo[3,2-f]quinolin-5-ato(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo[5.5.2]tetradecane)cobalt(III) triflate
    参考文献:
    名称:
    Cross-Bridged Cyclen or Cyclam Co(III) Complexes Containing Cytotoxic Ligands as Hypoxia-Activated Prodrugs
    摘要:
    A series of cobalt(III) complexes of the potent DNA minor groove alkylator (1-(chlorornethyl)-5-hydroxy-1H-pyrrolo [3,2-f]quinolin-3 (2H) -yl) (5,6,7- trim ethoxy-1H-indol-2-yl)methancine (3; seco-CPyI-TMI), with cyclam or cyclen auxiliary ligands (L3 and L5) containing a cross-bridging ethylene (CH2CH2) group or the N,N'-dimethyl derivatives of these (L4 and L6), was prepared. Two 8-quinolinato (2) model complexes of these, [Co(L3)(2)](ClO4)(2) and [Co(L6)(2)](ClO4)(2), and the aquated derivative [Co(L6)(H2O)(2)](OTf)(3) were characterized by X-ray Crystallography. Electrochemistry of the 8-quinolinato model complexes showed that the Co(III)/(II) reduction potential Was lowered relative to the unsubstituted cyclen ligand. Evaluation of the cytotoxicity of the racemic seco-CPyI cobalt complexes in vitro showed considerable attenuation of their cytotoxicity relative to the free alkylator and marked hypoxic selectivity, especially [Co(L3)(3)](2+) (9), which was 81-212-fold more potent under hypoxia than 20% oxygen in a panel of 10 human tumor cell lines. However, 9 did not elicit significant killing of hypoxic cells in HT29 tumor xenografts suggesting possible pharmacological limitations in vivo.
    DOI:
    10.1021/ic4006967
  • 作为产物:
    描述:
    三氟甲磺酸(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo[5.5.2]tetradecane)(carbonato)cobalt(III) chloride 反应 2.0h, 以65%的产率得到cis-bis(triflato)(4,10-dimethyl-1,4,7,10-tetraaza-bicyclo-[5.5.2]tetradecane)cobalt(III) triflate
    参考文献:
    名称:
    Cross-Bridged Cyclen or Cyclam Co(III) Complexes Containing Cytotoxic Ligands as Hypoxia-Activated Prodrugs
    摘要:
    A series of cobalt(III) complexes of the potent DNA minor groove alkylator (1-(chlorornethyl)-5-hydroxy-1H-pyrrolo [3,2-f]quinolin-3 (2H) -yl) (5,6,7- trim ethoxy-1H-indol-2-yl)methancine (3; seco-CPyI-TMI), with cyclam or cyclen auxiliary ligands (L3 and L5) containing a cross-bridging ethylene (CH2CH2) group or the N,N'-dimethyl derivatives of these (L4 and L6), was prepared. Two 8-quinolinato (2) model complexes of these, [Co(L3)(2)](ClO4)(2) and [Co(L6)(2)](ClO4)(2), and the aquated derivative [Co(L6)(H2O)(2)](OTf)(3) were characterized by X-ray Crystallography. Electrochemistry of the 8-quinolinato model complexes showed that the Co(III)/(II) reduction potential Was lowered relative to the unsubstituted cyclen ligand. Evaluation of the cytotoxicity of the racemic seco-CPyI cobalt complexes in vitro showed considerable attenuation of their cytotoxicity relative to the free alkylator and marked hypoxic selectivity, especially [Co(L3)(3)](2+) (9), which was 81-212-fold more potent under hypoxia than 20% oxygen in a panel of 10 human tumor cell lines. However, 9 did not elicit significant killing of hypoxic cells in HT29 tumor xenografts suggesting possible pharmacological limitations in vivo.
    DOI:
    10.1021/ic4006967
点击查看最新优质反应信息